The Credit Claim Deadline Is September 9, 2025 for all Registrant Types
Learners must visit the Center for Learning to claim credits commiserate with their engagement at ENDO.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates each activity in this course for a maximum of 24.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 24.75 Maintenance of Certification (MOC) points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. At the time of submission, please ensure your full name, Diplomate ID and birthdate match ABIM’s records or MOC points may be rejected by ABIM.
Successful completion of this CME activity, which includes participation in the overall conference evaluation in the Center for Learning, enables the learner to earn up to 23.75 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: European physicians attending an event in the USA had their credits recognized in Europe and American physicians attending an event in Europe had their credits recognized in the USA.
The Endocrine Society designates this educational activity for a maximum of 24.75 AMA PRA Category 1 Credit(s)™ for standard and premium registrants. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. Instructions regarding this conversion can be found here.
The Society is accredited by the American Council for Continuing Medical Education (ACCME). Credits awarded by organizations accredited by ACCME, such as AMA PRA Category 1 Credit™, are recognized by many other credentialing bodies as qualifying continuing education credits, such as the American Association of Nurse Practitioners (AANP), the American Association of Physician Associates (AAPA), the Certification Board for Diabetes Care and Education (CBDCE), and the Commission on Dietetic Registration (CDR). To claim continuing education credits for submission to these credentialing bodies, please claim participation credit and your certificate will display the appropriate AMA eligibility language needed.
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
Irina Bancos, MD, Elsevier, writer, Dynamed; Reviewer, Endocrine Society educational initiatives
Diane Donegan, Corcept, Investigator; Recordati, Advisory; Recordati, Investigator; HRA, Investigator; Endocrine Society, Speaker; Elsevier, Chapter Author
Christa E. Flueck, MD, Novo Nordisk, advisor, grantee; Merck, grantee; Pfizer, advisor, grantee; Sandoz, grantee, speaker; EffRx, advisor; Swiss National Science Foundation, grantee; European Society Paediatric Endocrinology, grantee, committee member
Oksana Hamidi, DO, Corcept Therapeutics, Advisory Board; Lantheus, Advisory Board; Neurocrine Biosciences, Advisory Board; Recordati Rare Diseases, Advisory Board; Xeris Pharma, Speaking engagement
Ole-Petter Hamnvik, MBBChBAO, MMSc, MRCPI, Education Editor, New England Journal of Medicine
Edward Chiaming Hsiao, MD, PhD, Clementia Pharmaceuticals/Ipsen Pharmaceuticals, Clinical trials site investigator at UCSF; Ultragenyx, Clinical trials site investigator at UCSF
Suzanne Jan De Beur, MD, Current Osteoporosis Reports, Associate Editor; Ultragenyx, Research, Advisory Board, Coordinating Author, consulting; Mereo Research; Kyowa Kirin, Advisory Board, research, DSMB; NIH, DSMB, PI, key personnel, grant reviewer; FDA, grant review; PCORI, Investigator; Ascendis, Advisory Board
Shingo Kajimura, PhD, Seminar Speaker, Novo Nordisk, Eli Lilly Amgen
Peter Kamenicky, MD, PhD, Governmental: Inserm, member of commission scientifique spécialisée CSS3; Pfizer, speaker and congress invitation; Amolyt Pharma, investigator, speaker and congress invitation; Ascendis Pharma, advisory board
Niki Karavataki, MSc, PhD, FRCP, Recordati Rare Diseases, Speaker; HRA Pharma, Speaker, Editorial Board; Pfizer, Speaker; Ipsen, Speaker; Conselient Health, Speaker
Katja Kiseljak-Vassiliades, DO, HRA Pharma, Adrenocortical Carcinoma Advisory Board
Monica Laronda, PhD, Dimension Inx, stock options
Raghavendra Mirmira, PhD, MD, Editor: Journal of Clinical Endocrinology and Metabolism, Advisory Board: Veralox Therapeutics
Connie Newman, MD, Food and Drug Association (FDA), member as of July 1, 2019 of Endocrinologic and Metabolic Diseases Advisory Committee; Medscape, Steering Committee Lipid Center of Excellence Honorarium; Federation of Medical Women of Canada Sept 2023, Honorarium
Gabrielle Page-Wilson, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma
Elizabeth Pearce, MD, MSc, Iodine Global Network: member of Management Council; Deputy Editor JCEM; Dynamed thyroid content editor; National Dairy Council, honoraria for speaking; Merck China Symposium, honoraria for speaking
Luca Persani, MD, PhD, Merck, speaker at scientific meeting & advisory boards; Sandoz, Scientific Board of IDEE 2024 meeting
Matti Poutanen, PhD, Aboendo, Founder & CEO, Forendo Pharma, Advisor, Organon Co., Advisor
Yumie Rhee, MD, PhD, Associate Editor, JCEM Case Reports
Laura Torchen, MD, Levo Therapeutics, site PI for carbetocin clinical trial; IBSA Pharma, site PI for Tirosint Sol clinical trial
W. Edward Visser, MD, PhD, Royalties (Institution): Egetis Therapeutics
Bu Beng Yeap, MBBS, FRACP, PhD, Advisory Board: NovoNordisk, Bayer, Advisor: Lawley Pharmaceuticals, Speaker: AstraZeneca, Besins, Philippine Society for Endocrinology, Diabetes and Metabolism, View Street Medical, President: Endocrine Society of Australia, Associate Editor: Asian Journal of Andrology, Journal of Gerontology Medical Sciences, Editorial Board: Journal of Gerontology Medical Sciences, Journal of Clinical Endocrinology and Metabolism, Maturitas
Elaine Wei-Yin Yu, MD, Grant Recipient: Amgen, Stock Owner: Opko
Ana Paula Abreu, MD, PhD; Benson Akingbemi, PhD, DVM; Olga Astapova, MD, PhD; Denise Belsham, PhD; Daniel Bernard, PhD; Laura Boucai, MD; Davide Calebiro, MD, Barbara Gisella Carranza Leon, MD; E. Danielle Dean, PhD; David A. Ehrman, MD; Hebatullah Ismail, MD; Sydney Jamison; Srividya Kidambi, MD; T. Raj Kumar, PhD, MPHIL, MSC; Richard McCosh, PhD; Erik Nelson, BSc, PhD; Claire Newton, BSc, PhD; Robin Peeters, MD, PhD; Ines Pineda Torra PhD; Julie Refardt, MD, PhD; Kimia Saleh Anaraki, MD; Kanakadurga Singer, MD; Ya-Xiong Tao, PhD; Marc J. Tetel, PhD; Theophilus Tettey, PhD; David Toro Tobon, MD; Elena Tsourdi, MD; Jean-Pierre Vilardaga, PhD; Corrine Welt, MD; and Jun Yang, MBBS, PhD, FRACP.
Disclosure information for presenters is included in their individual recorded presentations.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
